Image: Getty

Theranos and its founder, disgraced CEO Elizabeth Holmes, is getting sued by one of its biggest investors. The once promising biotech startup has been slowly crumbling since The Wall Street Journal challenged its claim that it could test blood with just a few drops last October.

Advertisement

The Wall Street Journal reports that Partner Fund Management LP, a hedge fund based in San Francisco, filed a lawsuit against the company for allegedly deceiving executives into investing $96.1 million into Theranos by claiming it had “proprietary technologies that worked.”

According to the Journal, PFM claims in the sealed lawsuit that:

Advertisement

Through a series of lies, material misstatements, and omissions, the defendants engaged in securities fraud and other violations by fraudulently inducing PFM to invest and maintain its investment in the company.

In response, Theranos told the Wall Street Journal that this lawsuit “is without merit and Theranos will fight it vigorously. The company is very appreciative of its strong investor base that understands and continues to support the company’s mission.”

In April, reports surfaced that Theranos was undergoing a criminal investigation for misleading its investors “about the state of its technology and operations.” The company has since voided two years of blood test results, effectively recalling its entire testing platform.

Sponsored

Last week, Holmes announced in an open letter that Theranos was shuttering its labs and wellness centers to focus on the company’s new miniLab device. In August, the company withdrew its application for FDA approval when federal regulators took issue with the miniLab device having improper patient safeguards. Despite this hiccup, the company will pursue this project likely because in July, Elizabeth Holmes was banned from operating labs for two years; pursuing the miniLab will allow Holmes to remain at her post.

Just one tech blogger’s opinion but hey, Theranos, have you considered giving up? I would say get out while you’re ahead, but it’s clearly too late for that.

Advertisement

Advertisement

[Wall Street Journal]